

## 1 Phage-plasmid borne methionine tRNA ligase mediates epidemiologically relevant 2 antimicrobial persistence

3 Yi Ling Tam<sup>1</sup>, P. Malaka De Silva<sup>2</sup>, Clare R. Barker<sup>3,10</sup>, Ruizhe Li<sup>4</sup>, Gherard Batisti  
4 Biffignandi<sup>2,6</sup>, Leanne Santos<sup>5</sup>, Charlotte E. Chong<sup>2</sup>, Lewis C. E. Mason<sup>7,8</sup>, Satheesh Nair<sup>9,10</sup>,  
5 Paolo Ribeca<sup>3,8,10,11</sup>, Sion C. Bayliss<sup>12</sup>, Claire Jenkins<sup>8,9</sup>, Somenath Bakshi<sup>4</sup>, James P.J. Hall<sup>5</sup>,  
6 Lauren Cowley<sup>1</sup>, Kate S. Baker<sup>2,8</sup>

7 <sup>^</sup> authors contributed equally      <sup>\*</sup> author to whom correspondence should be addressed: [kb827@cam.ac.uk](mailto:kb827@cam.ac.uk)

### 8 Affiliations

- 9 1. Milner Centre of Evolution, Department of Life Sciences, University of Bath, UK
- 10 2. Department of Genetics, University of Cambridge, Cambridge, CB2 3EH, UK
- 11 3. Gastrointestinal Infections & Food Safety (One Health), UK Health Security Agency, UK
- 12 4. Department of Engineering, University of Cambridge, Trumpington St, Cambridge, CB2 1PZ, UK
- 13 5. Department of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological  
14 Sciences, University of Liverpool, UK
- 15 6. European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome  
16 Campus, Hinxton, Cambridge CB10 1SD, UK
- 17 7. Department of Clinical Infection, Microbiology, and Immunology, Institute for Infection, Veterinary and  
18 Ecological Sciences, Liverpool, UK
- 19 8. NIHR HPRU in Gastrointestinal Infections at University of Liverpool, Liverpool, UK
- 20 9. Gastrointestinal Bacteria Reference Unit, UK Health Security Agency, UK
- 21 10. NIHR HPRU in Genomics & Enabling Data at University of Warwick, Warwick, UK
- 22 11. Biomathematics and Statistics Scotland, The James Hutton Institute, Edinburgh, UK
- 23 12. Bristol Veterinary School, Faculty of Health and Life Sciences, University of Bristol, UK.

### 24 25 Abstract (226 words)

26 Antimicrobial resistance (AMR) is a global public health crisis with few options for control. As  
27 such early identification of emerging bacterial strains capable of rapidly evolving AMR is key.  
28 Although antimicrobial tolerance and persistence are precursor phenotypes for AMR, little  
29 evidence exists to support their importance in real-world settings. Here we used bacterial  
30 genome wide association on national genomic surveillance data of the diarrhoeal  
31 pathogen *Shigella sonnei* (n=3745) to agnostically identify common genetic signatures among  
32 lineages convergently evolving toward AMR (n=15). This revealed an association of an AMR  
33 trajectory with a multi-and highly variable second copy of *metG*, borne by a phage-plasmid we  
34 called pWPMR2. Further analyses revealed that pWPMR2 was present across clinically  
35 relevant enteric pathogens globally, including past and contemporary outbreaks, and that the  
36 additional-*metG* mechanism was present across multiple bacterial phyla. Functional  
37 microbiology, experimental evolution, and single-cell physiology studies confirmed that the  
38 expression of auxiliary *metG*, particularly the mutated version on pWPMR2, created a sub  
39 population of persister cells predisposed to survival in, and evolving resistance against, third  
40 generation cephalosporins. Thus, we demonstrate a novel mechanism of auxiliary *metG*  
41 carriage that predisposes bacteria to AMR with real world impacts. Furthermore, our approach  
42 is a timely example of using genomic epidemiology to rapidly guide functional microbiology  
43 studies in the era of routine genomic surveillance, and also highlights several deficiencies in  
44 current AMR surveillance practices.

45

## 46 **Background (4091 words in main text)**

47

48 Antimicrobial resistance (AMR) is a global public health crisis, and microbial genomics has  
49 revealed that certain highly AMR bacterial lineages dominate epidemiologically. For example,  
50 *S. Typhimurium* Sequence Type 313 (ST313) in African invasive disease <sup>1</sup>, the pandemic *E.*  
51 *coli* ST131 <sup>2-5</sup>, the carbapenemase associated *K. pneumoniae* ST258 <sup>6</sup>, and Lineage III *S.*  
52 *sonnei* which has recently evolved extensive drug resistance (XDR) <sup>7-9</sup>. Once AMR has been  
53 acquired and disseminated in these successful clones, the resulting treatment complications  
54 make their control challenging. In an ideal world, we would use the imminent tsunami of  
55 genomic surveillance data to move toward predictive frameworks of AMR surveillance in which  
56 clones that are predisposed to AMR could be identified for timely intervention. However, this  
57 requires an understanding of the precursors or ‘stepping stones’ that occur before AMR  
58 evolves, or is acquired.

59

60 Here, we leveraged an epidemiological scenario of convergent evolution of AMR among  
61 lineages of a highly clonal pathogen to agnostically identify pathogen-factors associated with  
62 an AMR trajectory. Specifically, the severe diarrhoeal pathogen, *Shigella*, has established  
63 over the last two decades as a sexually transmissible illness (STI) among men who have sex  
64 with men (MSM) <sup>10</sup>. This is particularly detectable in traditionally non-endemic, high-income  
65 countries, such as the United States and the United Kingdom, where an over-representation  
66 of closely related isolates derived from males without a recent history of travel is used to  
67 identify lineages that are circulating in sexual transmission networks (STN) <sup>11,12</sup>. Studies have  
68 shown that, at a given time, there are multiple co-circulating STN Lineages of *Shigella* and  
69 that these are subject to high levels of antimicrobial selection pressure <sup>9,13,14</sup>. This pressure is  
70 evidenced by convergent acquisition of AMR plasmids and the development of bystander  
71 resistance thought to result from high intensity treatment for other traditional STIs <sup>9,10,14-16</sup>.  
72 Concerningly, it is also clear that these lineages spread globally over short time frames and  
73 share plasmids among themselves and with other pathogen groups. Thus, convergently  
74 evolving genetic traits among co-circulating STN Lineages of *Shigella* represent adaptations  
75 potentially associated with a trajectory to AMR that could rapidly spread.

76

77 In this study, we identify convergently evolving factors across 15 STN lineages among some  
78 3,745 *Shigella sonnei* isolates from routine surveillance in the United Kingdom using bacterial  
79 Genome Wide Association Study (bGWAS) to identify ‘stepping stones’ to AMR. We identified  
80 variant copies of methionine tRNA ligase (*metG*) carried on an SSU5-like phage-plasmid,  
81 which we called pWPMR2, as associated with STN Lineages (a proxy for high antimicrobial  
82 selection). Further *in silico* analyses showed that both pWPMR2 and other plasmid-borne  
83 *metG* are spread globally in other enteric bacteria and bacterial phyla. We demonstrate how  
84 auxiliary *metG* expression and variation create bacteria with persister phenotypes that  
85 predispose bacteria to evolve AMR against third generation cephalosporins.

## 86 **Phage-plasmid borne *metG* is associated with an AMR trajectory**

87 To identify genetic features associated with AMR emergence, we first identified convergently  
88 evolving STN lineages of *S. sonnei*. To do this, we constructed a recombination-free  
89 maximum-likelihood phylogenetic tree of *S. sonnei* isolates (n=3,745) from surveillance in the  
90 United Kingdom between 2004 and 2020 (Figure 1A, Extended data). Adapting validated  
91 approaches, we then used demographic data on patients’ age, sex, and travel history for

92 ancestral state reconstruction to identify 15 lineages circulating in STN (hereafter STN  
93 lineages, Figure 1A, Table1, Extended Data, Methods). We identified 15 STN lineages of  
94 variable sizes which, consistent with the increased antimicrobial selection pressure in STN,  
95 had a significantly higher proportion of isolates containing genes conferring AMR against (any  
96 of) the three main clinically relevant antimicrobials for *Shigella*<sup>17</sup>; ciprofloxacin (CIP),  
97 azithromycin (AZM), and ceftriaxone (CRO) (74% [n=765/1,028] compared with 37%  
98 [n=1011/2,717], p-value <0.001, Table 1, Supplementary Data). Alongside the distribution of  
99 these resistances in five, six, and five of the 15 STN lineages respectively this confirms that  
100 *Shigella* circulating in STN are convergently evolving toward AMR, consistent with previous  
101 studies<sup>10,14,16,18–20</sup>.

102  
103 We then quantified the association of unique genetic sequences (i.e. unitigs from a compiled  
104 assembly graph of the 3,745 isolates) with membership of STN Lineages using treeWAS<sup>21</sup>.  
105 We identified a total of 229,603 unitigs which had varying degrees of association with STN  
106 lineages (Figure 1B). This approach was deemed valid as unitigs related to AZM resistance  
107 genes (*mphA*, n=157 and *ermB*, n=54) had some of the highest association scores (Figure  
108 1B), and AZM resistance is known to have emerged globally among *Shigella* in STN<sup>10,14,16,18–</sup>  
109 <sup>20</sup> (Figure 1A). Among the highly associated unitigs (>0.66 association score, Extended data)  
110 we also found sequences (n=357) relating to *metG*, which encodes the methionine tRNA  
111 ligase, MetG (also known as methionine tRNA synthetase). MetG plays a core role in  
112 translation by linking the start codon amino acid, methionine, to its cognate tRNA molecule.  
113 Disruptions in *metG* have been studied in laboratory settings and are associated with altered  
114 growth characteristics and antimicrobial tolerance (i.e. short-term survival against killing  
115 concentrations of antimicrobials without a shift in AMR phenotype<sup>22–25</sup>, and predisposition to  
116 AMR<sup>26</sup>). Thus, we hypothesised that the auxiliary *metG* was playing a role in the adaptation  
117 of *Shigella* lineages to circulation in the high antimicrobial selection environment of STNs.

118  
119 Bioinformatic analyses to explore the nature of the *metG* association revealed both copy  
120 number variation and Single Nucleotide Polymorphisms (SNPs, Extended data) which we  
121 explored in turn. Complementary long-read sequencing of STN Lineage 12 strain  
122 SRR5005407 (Figure 1A) revealed an extra copy of *metG* was carried on a 108,107bp circular  
123 sequence containing both plasmid, and phage sequences (Figure 1C), i.e. a phage-plasmid,  
124 which we called pWPMR2 (GenBank accession: PQ180110). Reference mapping to the  
125 chromosome and pWPMR2 then revealed variation in copy number (relative depth of  
126 pWPMR2 to chromosomal mapping coverage) and coverage (proportion of pWPMR2 sites  
127 covered) of pWPMR2 among the *S. sonnei* isolates (Extended data). By employing cut offs  
128 (0.22 relative depth, 0.7 coverage), we inferred that 650 *S. sonnei* isolates contained pWPMR2  
129 which were mostly (87%, n=566/650, p<2.2e-16) associated with STN lineages (Figure 1A,  
130 Table 1, Extended data). While most pWPMR2-containing isolates contained one to two  
131 copies of pWPMR2, there was a wide range of relative depth (Extended data), suggesting  
132 some instability in pWPMR2 carriage, consistent with the acquisition of an essential gene<sup>27</sup>.  
133 Mapping coverage further suggested the presence of a *metG*-bearing pWPMR2 variant  
134 (pWPMR2var) with reduced (~0.75) coverage (Figure 1A, Table 1, Extended data, GenBank  
135 accession: PQ521219 from isolate SRR10313630). Consistent with it being a phage-plasmid,  
136 pWPMR2 contained an anti-defence system, RAD, previously described as targeting retrons  
137<sup>28</sup>. No known AMR or virulence genes were present on pWPMR2, so we continued with our  
138 GWAS-guided hypothesis that auxiliary *metG* expression was driving a phenotypic shift  
139 relevant for adaptation to antimicrobial selection pressure.

140

STN Lineage*	Isolates, n	pWPMR2-bearing isolates, n (%)	Dominant genotype^ (% belonging to lineage)
1	580	463 (80)	3.6.1.1.2 (100)
2	22	2 (9)	3.6.1.1.3.1 (77)
3	13	11 (85)	3.6.1.1 (100)
4	6	0 (0)	3.6.1.1 (100)
5	27	12 (44)	3.6.1.1.3.1 (85)
6	5	2 (40)	3.6.1 (100)
7	5	0 (0)	3.6.3 (100)
8	9	0 (0)	3.6.2 (100)
9	176	37 (21)	3.7.25 (100)
10	15	5 (33)	3.7.18 (100)
11	11	0 (0)	3.7.4 (100)
12	125	27 (22)	3.7.29.1.2 (66)
13	6	0 (0)	3.4.1 (100)
14	14	6 (43)	3.1 (100)
15	14	1 (7)	2.11.4 (71)
<b>STN Lineages subtotal</b>	<b>1028</b>	<b>566 (55)</b>	
Non-STN Lineages	2717	84 <sup>&amp;</sup> (0.03)	
<b>Total</b>	<b>3745</b>	<b>650 (17)</b>	

141

142

**Table 1. Characteristics of *S. sonnei* lineages circulating in STNs**

143

\* arbitrarily named from top to bottom of tree in Figure 1A – see Supplementary Data for individual assignments

144

^ genotyping performed according to<sup>20</sup>

145


<sup>&</sup> 53 of which were pWPMR2var

146

147

An analysis of SNPs across *metG* among the isolates revealed that the auxiliary *metG* on pWPMR2 exhibited significant genetic variation relative to the essential chromosomal version. Specifically, isolates without pWPMR2 (i.e. only chromosomal *metG*) showed high levels of conservation, with only 12 of 3095 isolates containing SNPs across five sites in *metG*; four of which introduced non-synonymous changes (found in non-STN Lineages not phylogenetically proximate to STN Lineages), and one synonymous change in seven isolates of STN Lineage 15. Contrastingly, isolates that contained pWPMR2 had significant numbers of SNPs (0-118 per isolate, mean 66) affecting a total of 250 sites across the 2034bp gene, at minor allele frequencies consistent with a low-copy number mobile genetic element (Extended data). A sliding window analysis of the variation (density of SNPs) on *metG* showed relative sequence conservation in certain key functional areas of the gene (such as the HIGH and KMSK amino acid motifs) and comparatively higher variation in the N6-acetyllysine sites (Figure 1D), which might alter *metG* post-translational modification and abundance<sup>29,30</sup>, with a knock-on effect on overall protein production. While quantitating gene variation in multicopy genes using short read data is complex our complete genome sequencing confirmed that, the *metG* borne by pWPMR2 in our reference isolate SRR5005407 (see metG<sub>PP</sub> below) contained 115 SNPs, 6 of which were non-synonymous. This highlights that the additional *metG* on pWPMR2 experiences significant mutation relative to single chromosomal copies.

165



166  
 167  
 168 **Figure 1. Variable *metG* borne on pWPMR2 is associated with bacterial lineages on an AMR trajectory.**  
 169 A midpoint-rooted maximum likelihood phylogenetic tree constructed from 32,294 recombination-free polymorphic  
 170 sites shows the evolutionary relationships among 3,745 routine genomic surveillance *S. sonnei* isolates. The  
 171 adjacent metadata columns show (from left to right): STN lineages (i.e. circulating in sexual transmission networks);  
 172 the presence of pWPMR2 or pWPMR2var, and the presence of genotypically predicted resistance against three  
 173 key antimicrobial treatments; azithromycin (AZM), ceftriaxone (CRO), and ciprofloxacin (CIP). The two isolates  
 174 used to nanopore sequence pWPMR2 and pWPMR2var are indicated by arrows. **B.** Frequency histograms show  
 175 the distribution of Genome Wide Association Scores. Distributions are shown for all units  $\geq 0.05$  minor allele  
 176 frequency ( $n=229,560$ ) among the isolates, and units relating to the AZM resistance genes *mphA* and *ermB*  
 177 (acting here as positive controls) and *metG*. **C.** A genetic map of the phage-plasmid pWPMR2 showing forward  
 178 (outer) and reverse (inner) open reading frames coloured by function according to the inlaid key. **D.** The variation  
 179 in *metG* across the length of the gene among 650 pWPMR2/pWPMR2var-containing isolates. Median (solid) and  
 180 interquartile-range quantiles (dashed) of SNP-density across the gene are indicated by horizontal lines and a sliding  
 181 60bp window of SNP-density (undulating line).

## 182 pWPMR2 and auxiliary *metG* are found globally in other clinically relevant organisms

183 Having associated a novel *metG*-bearing mobile genetic element with genomic lineages on  
 184 an AMR trajectory, we then explored the extent to which pWPMR2 may have spread among  
 185 clinically relevant organisms. A comparison of near-identical relatives of pWPMR2 in public  
 186 databases revealed that it was present in multiple other major outbreaks of *Shigella* and Shiga-

187 toxigenic *E. coli* and may have links with *E. albertii*. Specifically, it was near-identical (>99%  
188 similarity) to several undescribed plasmids from MSM-associated outbreaks of *S. sonnei*<sup>16,18</sup>  
189 and O117:H7 Shiga toxin-producing *E. coli* (STEC)<sup>31</sup>, across a broad geographical range  
190 (Figure 2A). A closely related element was also found to be present in an isolate belonging to  
191 an STEC O114:H4 outbreak in Georgia in 2009<sup>32</sup>, as well as an AZM-resistance bearing  
192 commensal *E. coli* strain (ST62) from a healthy college student in the USA<sup>33</sup>. Outside of  
193 *Shigella* and *E. coli* the closest relatives were found in *E. albertii* where multiple regions of  
194 pWPMR2 were absent (Extended data). This demonstrated that pWPMR2 is a widely  
195 distributed mobile genetic element associated with important outbreaks of clinical disease as  
196 well as commensal organisms.

197  
198 To further explore its association with clinically relevant organisms, we determined the  
199 taxonomy of pWPMR2 and screened all genomes of enteric infections in the UK isolated  
200 between 2016 and 2021 (n=66,929) for evidence of pWPMR2-like phage plasmids.  
201 Taxonomically, pWPMR2 was found to belong to the SSU5 super-community of phage-  
202 plasmids that are associated with species of the *Enterobacteriaceae* family<sup>34</sup>. Comparison of  
203 its genome-wide sequence similarity with other phage genomes showed that pWPMR2  
204 belonged within the pSLy3 group (Figure 2B, Extended data). The screen of clinical isolates  
205 from enteric infections revealed that while SSU5 phage-plasmids were present in isolates from  
206 all genera, the pSLy3-like group was primarily associated with *S. sonnei* (18% of isolates), *E.*  
207 *albertii* (8%), *E. coli* (2%), and other *Shigella* species (0.5%, Table 2). This indicates the  
208 mobilisation of pWPMR2 across multiple enteric pathogen species, consistent with previous  
209 observations for AMR plasmids<sup>14,35</sup>.

210

Species	Genomes (n)	SSU5 supercommunity phage plasmid group containing (n)					
		pHCM2	pSLy3	pKpn <sup>1</sup>	pCAV <sup>1</sup>	pMT1 <sup>2</sup>	Other
<i>S. enterica</i>	47,495	539	0	0	0	0	2
<i>E. coli</i>	11,990	5	236	0	0	0	0
<i>E. albertii</i>	173	0	8	0	0	0	0
<i>S. sonnei</i>	3,427	2	628	0	0	0	0
<i>S. flexneri</i>	3,259	1	15	0	0	0	0
<i>S. dysenteriae</i>	196	0	0	0	0	0	0
<i>S. boydii</i>	289	0	4	0	0	0	0
<b>Total</b>	66,829	547	891	0	0	0	2


211 **Table 2. The presence of SSU5-like phage plasmid subtypes across enteric bacteria in the UK**

212 <sup>1</sup> restricted to *Klebsiella* in GenBank <sup>2</sup> restricted to *Yersinia* in GenBank.

213

214

215




216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234

**Figure 2. Epidemiological and taxonomic relatives of pWPMR2.** **A.** Comparison of pWPMR2 with its most similar publicly available sequences (labelled leftmost) and their epidemiological details. The sequence comparison is shown as linearised replicons starting with *repB* gene. Certain relevant gene features are shown in colour and labelled uppermost. Colour blocks intervening between sequences showing colinear (blue scale) and inverted (red scale) synteny according to the inlaid coloured gradient keys. The origin of the sequence, country and organism are shown to the right of sequences. The symbol key for origin is shown leftmost. Other available details for the sequences (e.g. subtype, year of isolation) are shown under the sequence label. STEC = Shiga toxin-producing *Escherichia coli*. STN-A = Sexual Transmission Network associated. **B.** The circular cladogram shows comparison among 1,512 related reference viral sequences (see methods). The branch lengths show genetic relatedness based on tBLASTx comparison (embedded in VIP tree) on a non-linear scale. The inner and outer rings show virus family and host group according to the inlaid keys, and the SSU5 community is highlighted as a red branch. The pop out shows a SSU5 community cladogram, highlighting the pSLy3 group, containing pWPMR2 (orange) and pWPMR2var (yellow).

Given this evidence that pWPMR2 could spread across pathogens, we more fully characterised the temporospatial spread of pWPMR2. We first determined the temporal relationship of pWPMR2 acquisition with AMR across our 3,745 *S. sonnei* surveillance isolates

235 (Figure 3A). This showed that pWPMR2 entered the *S. sonnei* population earlier than, and  
236 then had similar temporal increases to, key AMR genotypes (e.g. the plasmid-borne AZM and  
237 CRO resistances). This stepwise acquisition is clear in the internationally disseminated XDR  
238 Genotype 3.6.1.1.2 (STN Lineage 1 in Figure 1A, Supplementary table, Figure 1A<sup>9</sup>). This pre-  
239 AMR acquisition is consistent with pWPMR2 conferring a phenotype relevant to the  
240 emergence of AMR. To explore spatial spread, we screened for pWPMR2 in over 2 million  
241 bacterial genome sequences in the public domain (Methods), and found it was spread among  
242 some 2,028 *E. coli* and *Shigella* isolates from broad geographical areas, often in isolates  
243 derived from public health surveillance (Figure 3B, Extended data). This built further genomic  
244 epidemiological evidence that pWPMR2 is an emerging mobile genetic element capable of  
245 spreading among pathogenic organisms.  
246



247  
248  
249  
250  
251  
252  
253  
254  
255

**Figure 3. Temporal and spatial patterns of pWPMR2.** **A.** The exponential growth in frequency of isolates containing pWPMR2, and resistance markers against three key antimicrobials among 3,745 *S. sonnei* surveillance isolates is shown over time according to the inlaid key, highlighting the early ingress of pWPMR2 into the *S. sonnei* population. **B.** The global distribution of 2,028 pWPMR2-containing isolates in public databases is shown with countries containing sequences highlighted in darker grey. Bubbles over country centroids are shown scaled by the number of isolates and coloured by the organism of origin according to the inlaid keys.



256 To explore the relevance of auxiliary *metG* in the broader bacterial context, we screened  
257 sequences (n=59,895) from the PLSDB plasmid database<sup>36</sup> for *metG*, and other tRNA ligases.  
258 This revealed that tRNA ligase homologues were found at low levels on plasmids  
259 (n=513/59895, 0.86%, Extended data). Following filtration for potential chromosomal  
260 contamination (Methods), five tRNA ligases were found on an appreciable number ( $\geq 20$ ) of  
261 plasmids: *alaS*, *cysS*, *metG*, *serS*, *thrS*. Of these, *metG* was outstanding as the most  
262 frequently observed tRNA ligase, detected more often than all the other tRNA ligases put  
263 together, and the only one found >5 times in >1 Family. Specifically, *metG* encoding plasmids  
264 were predominantly found in Enterobacteriaceae (n=172/29242, 0.59%) and  
265 Burkholderiaceae (*Ralstonia* spp., n=95/652, 14.57%). While the Enterobacteriaceae  
266 plasmids were overwhelmingly (n=165/172) recorded in the database as an FIB phage-  
267 plasmid type (consistent with pWPMR2 detection), the *Ralstonia* plasmids were putative  
268 chromids (large, domesticated plasmids associated with environmental adaptation) ranging  
269 from 1.78 Mb to 2.2 Mb<sup>(37)</sup>, Extended data). As widespread plant pathogens, *Ralstonia* can  
270 experience both environmental (e.g. produced by niche competitors) and human (e.g. through  
271 agricultural practices) derived antimicrobial selection pressure<sup>38</sup>, so may be served by  
272 functional phenotypes that would be advantageous in adapting to significant antimicrobial  
273 selection pressure.


#### 274 **Mutated *metG* confers evolutionary advantages in the presence of ceftriaxone**

275 Having determined that *metG* was borne on multiple mobile genetic elements, we sought to  
276 explore phenotypes associated with auxiliary *metG* expression and the reduced mutational  
277 constraint detected in pWPMR2. Specifically, we conducted laboratory experiments on growth  
278 characteristics and antimicrobial response phenotypes of DH5 $\alpha$  *E. coli* mutants containing  
279 inducible vectors that expressed wildtype (i.e. *S. sonnei* chromosomal) *metG* (hereafter  
280 *metG<sub>WT</sub>*) and the mutated version found on pWPMR2 (hereafter *metG<sub>PP</sub>*). We first confirmed  
281 that *metG* expression did not result in a change in AMR phenotypes, finding Minimum  
282 Inhibitory Concentrations (MIC) consistent across strains (Extended data). Bulk growth  
283 experiments then revealed that induction of either *metG<sub>WT</sub>* or *metG<sub>PP</sub>* reduced bacterial growth,  
284 with *metG<sub>WT</sub>* introducing an increased lag time (consistent with a previously reported tolerance  
285 by lag phenotype<sup>39</sup>) and *metG<sub>PP</sub>* expression generating diauxic growth (Figure 4A). Using  
286 these constructs, we then determined the impact of auxiliary *metG* expression (by comparing  
287 *metG<sub>WT</sub>* with expression induced and uninduced) and *metG* variation (by comparing induced  
288 *metG<sub>WT</sub>* with induced *metG<sub>PP</sub>*) in various phenotypic assays.

289  
290 As MICs had not changed, we explored a potential benefit of auxiliary *metG* in the presence  
291 of sub-inhibitory concentrations of antimicrobials, comparing the relative growth (as measured  
292 by ratios of Area Under the Curve, AUC) of constructs in a reduced concentration (0.5 MIC)  
293 of AZM, CIP and CRO. This revealed that *metG<sub>WT</sub>* expression posed no additional fitness cost  
294 in the presence of subinhibitory concentrations of CRO, despite being costly in the presence  
295 of subinhibitory concentrations AZM and CIP (Figure 4B). Similar effects were also seen in  
296 comparing the impact of the variation found in *metG* (i.e. the growth performance of *metG<sub>PP</sub>*  
297 relative to *metG<sub>WT</sub>*, Figure 4B). This suggested that auxiliary *metG* expression, particularly the  
298 mutated form on pWPMR2, might provide a fitness advantage in coping with exposure to  
299 subinhibitory concentrations of CRO.

300

301 To determine the role of *metG* expression and variation in the adaptation to supra-MIC  
 302 concentrations, we conducted an experimental evolution of 47 independent populations of *E.*  
 303 *coli* expressing *metG*<sub>WT</sub> and *metG*<sub>PP</sub> for twelve days, doubling antimicrobial concentration daily  
 304 (Methods, Figure 4C). Although all *metG*<sub>WT</sub> populations (induced and uninduced) died by the  
 305 end of the experiment, expression of auxiliary *metG* adversely affected survival (Figure 4C,  
 306 top panel). However, this negative impact on survival was ameliorated in the case of *metG*<sub>PP</sub>  
 307 expression (Figure 4C bottom panel; Log-rank tests: AZM  $p=0.005$ , CIP,  $p=6e-6$ , CRO  
 308  $p=0.03$ ). Furthermore, evolution of *metG*<sub>PP</sub> against CRO was the only condition with surviving  
 309 populations ( $n=4$ ) from the final exposure at 1024X MIC. Thus, our results collectively indicate  
 310 an advantage is offered by the mutations observed on *metG* in the presence of both sub- and  
 311 supra- inhibitory concentrations of CRO.  
 312



313  
 314  
 315 **Figure 4. Auxiliary *metG* expression and variation generates altered growth profiles and antimicrobial**  
 316 **response phenotypes. A.** Growth over time for *E. coli* DH5 $\alpha$  constructs with auxiliary *metG*<sub>WT</sub> expression induced  
 317 (*metG*<sub>WTi</sub>) and the respective (i.e. uninduced) control (*metG*<sub>WTu</sub>) and the induced pWPMR2 version of *metG*  
 318 (*metG*<sub>PPi</sub>). **B.** Relative growth of constructs in the presence of subinhibitory concentrations of key treatment  
 319 antimicrobials (0.5X MIC) shown for auxiliary *metG* expression (left, *metG*<sub>WTi</sub> relative to *metG*<sub>WTu</sub>) and variation  
 320 (right, *metG*<sub>PPi</sub> relative to *metG*<sub>WTi</sub>). **C.** Population survival curves of *E. coli* constructs induced to express  
 321 auxiliary *metG*<sub>WT</sub> (*metG*<sub>WTi</sub>) and uninduced (*metG*<sub>WTu</sub>) [upper] and *metG*<sub>WTi</sub> relative to the pWPMR2 version  
 322 (*metG*<sub>PPi</sub>) [lower panel]. CRO = ceftriaxone, AZM = azithromycin, CIP = ciprofloxacin AUC = area under the curve.  
 323

324  
 325 ***metG*<sub>PP</sub> facilitated survival in CRO is mediated by multiple phenotypes**  
 326 To further resolve the observed advantages in response to CRO, we conducted time-resolved  
 327 single-cell analysis of the CRO response in strains carrying inducible *metG*<sub>WT</sub> or *metG*<sub>PP</sub>  
 328 plasmids. Briefly, plasmids were introduced into *E. coli* strains carrying a constitutively  
 329 expressed (under the PrpsL promoter), chromosomally integrated Cyan or Yellow  
 330 Fluorescence Protein<sup>40</sup> to distinguish pooled strains, and a plasmid-free background strain,


331 constitutively expressing Red Fluorescence Protein (Figure 5A). The mixed population of three  
332 strains was loaded into two separate lanes of a high-throughput microfluidic device<sup>41</sup> such  
333 that cells were loaded into trenches randomly within each lane to eliminate systematic biases.  
334 In this setup, cells in one lane were exposed to media containing the *metG* inducer, while cells  
335 in the other lane received media without the inducer. The narrow trench design of the  
336 microfluidic device ensured that the progeny of the cell type occupying the closed end of a  
337 trench (the MOTHER cell) replaced cells below, resulting in a pure genotype per trench over  
338 time (example of three trenches with randomised loading and eventual purification are shown  
339 in Figure 5B). Thus, mixed fluorescence populations, and use of multiple specifically designed  
340 microfluidic devices allowed us to compare the effects of *metG* auxiliary expression, similarly  
341 as above, but at a single cell level.

342  
343 We then used this set up to precisely track and analyse the growth and response phenotypes  
344 of each genotype towards high-dose CRO treatment (50X MIC for 2 hours from stationary  
345 phase). An example time series of cell length from an untreated cell is shown in Figure 5C to  
346 indicate variables at baseline in contrast with the diverse response phenotypes observed  
347 during and after CRO treatment (Figure 5D). These diverse response phenotypes were  
348 classified into four distinct categories including two terminal phenotypes: 1. Cells that visibly  
349 lysed or 2. Cells that form long filaments; 3. Viable, But Non Culturable (VBNC), cells that did  
350 not grow during or after treatment; and 4. Recovered cells capable of normal growth after  
351 treatment. Recovered cells were further divided into two subcategories: Persisters that exited  
352 dormancy, and resumed growth, after CRO was removed and Short filament formers that  
353 formed short filaments during treatment and resolved into planktonic cells once the antibiotic  
354 was removed through a series of asymmetric divisions. Critically, in the absence of the  
355 inducer, strains carrying both *metG<sub>WT</sub>* or *metG<sub>PP</sub>* plasmids showed similar CRO response  
356 profiles (see comparable phenotype proportions in Figure 5E) highlighting their utility as  
357 controls.

358  
359 The effect of expressing auxiliary *metG* was then captured through *metG<sub>WT</sub>* induction which  
360 resulted in a drastic reduction of VBNCs. All cells exited dormancy and resumed growth during  
361 CRO treatment with entirely lethal outcomes (i.e. the entire population either lysed or formed  
362 long filaments, Figure 5E). This dormancy exit was facilitated by a reduced lag time (defined  
363 as the time to reach 1.5X the dormant cell size; Figure 5C). The comparison of lag time  
364 distributions between uninduced and induced *metG<sub>WT</sub>* populations showed that expression  
365 caused all cells to exit dormancy during treatment leaving them susceptible to CRO-induced  
366 killing (Figure 5F). This finding is consistent with prior results demonstrating that *metG* is  
367 essential for dormancy exit; an extra copy accelerates this process, while a mutated version  
368 slows it down<sup>42</sup>. Additionally, the induction of *metG<sub>WT</sub>* increased the probability of dormancy  
369 exit, evidenced by the reduced fraction of VBNC cells. However, this also reduced overall  
370 survival, aligning with bulk observations (Figure 4C, top panel).

371  
372 Turning then to the effect of *metG* variation, while induction of *metG<sub>PP</sub>* also reduced VBNC  
373 fractions (though to a lesser extent than induction of *metG<sub>WT</sub>*), it increased the fraction of  
374 recovered cells (Figure 5E). Lag time distributions revealed that *metG<sub>PP</sub>* expression led to a  
375 higher proportion of persister cells (i.e. those with lag times longer than the treatment period)  
376 and cells that formed short filaments during treatment but resolved after CRO was removed  
377 (i.e. still recovered, but with lag times shorter than the treatment period, Figure 5G). This  
378 distinction was further supported by cell length distributions of recovered cells immediately

379 after CRO removal (Figure 5H). Specifically, induction of *metG<sub>PP</sub>* resulted in a greater fraction  
 380 of longer cells at the point of CRO removal, which subsequently resolved into regular-sized  
 381 cells, suggesting that *metG<sub>PP</sub>* introduces greater variability into lag times compared to the wild-  
 382 type version. This variability facilitates a bet-hedging strategy, where longer lag times allow  
 383 cells to persist through treatment, and shorter lag times enable early exit from dormancy,  
 384 leading to filament formation during treatment with recovery to normal division post-treatment.  
 385



386  
 387

**Figure 5: Single-cell analysis of CRO response of *metG<sub>WT</sub>* and *metG<sub>PP</sub>* carrying cells**

388 **A.** A schematic of the high throughput microfluidics device for pooled single cell time lapse experiment. Individual  
 389 lanes are used to load and treat cells under induced or uninduced conditions. Each lane contains narrow trenches  
 390 (1.3µm wide) to house isolated cell lineages of cells from a randomised pool (*E. coli* carrying *metG<sub>WT</sub>* and *metG<sub>PP</sub>*,  
 391 and their background strain). Strains randomly occupy positions within individual trenches, but the progenies of the  
 392 cell at the closed end (referred to as the mother cell) eventually occupy the trench, causing each trench to have a  
 393 pure genotype. Individual cell lineages from all strains are randomly distributed across trenches and share a  
 394 homogeneous treatment and growth condition from media flowing in the lane throughout specified time. Three  
 395 example trench images including mixed strains at t=0, where different genotypes occupy the mother position, are  
 396 shown. Each trench was identified by the "mother cell" located at the closed end of the trench. **B.** Three example  
 397 timelapses of each trench shown in (A) are shown overtime. The trenches were occupied by the progenies of the  
 398 mother cell as they were grown from t=0. **C.** Example cell-length time series and key growth parameters measured.  
 399 The cell-length time series were obtained by segmentation and tracking of individual cells from stationary phase to  
 400

401 exponential growth. From these traces, key single cell growth parameters were determined including lag time,  
402 growth rate, and generation time. **D.** Example cell-length traces leading to different fates from CRO treatment (50X  
403 MIC, 2h). A fraction of cells lyse during treatment (Pink) or form long filaments which are both considered terminal  
404 phenotypes. Blue traces are categorised as VBNC cells which show no visible signs of growth. Green traces  
405 represent cells that can recover normal growth after treatment, including cells that are dormant throughout  
406 treatment and resuscitate after the antibiotic is removed (Persisters) and cells that form short filaments and resolve  
407 into regular sized cells after the antibiotic is removed (Short filament formers). **E.** Proportion of cell fates after CRO  
408 treatment shifted by  $metG_{WT}$  and  $metG_{PP}$  expression. Fractions were obtained by bootstrapping approximately 200  
409 cells for each strain. Inducing  $metG_{WT}$  caused most cells to lyse and reduce the fraction of VBNC, while inducing  
410  $metG_{PP}$  led to more cells recovered from the treatment, i.e., reduced lysis and VBNC population. **F.** Lag time  
411 distribution of  $metG_{WTu}$  and  $metG_{WTi}$  cells. Recovered cells are shown as green dots with drug removal indicated  
412 by a dashed line. Most  $metG_{WTi}$  cells have exited dormancy before the drug is removed. **G.** Lag time distribution  
413 of  $metG_{PPu}$  and  $metG_{PPi}$  cells. Recovered cells are shown as green dots with drug removal indicated by a dashed  
414 line. The  $metG_{PPi}$  were able to recover cells that had exited from a wide range of time points. All the cells that  
415 exited dormancy after drug removal were able to recover. **H.** Cell size of  $metG_{PP}$  populations just before treatment  
416 recovery; many  $metG_{PPi}$  cells resolved from filamentation through a sequence of asymmetric divisions.

417

## 418 **Epilogue: a real-time outbreak underlines the role of pWPMR2**

419 During the period of this work, pWPMR2 was also involved in a new sexually transmitted  
420 outbreak of XDR *S. sonnei* that took place in England in 2023. The outbreak comprised 120  
421 cases within a 10-SNP-surveillance-cluster that occurred from 2022 – 2023 with most  
422 (n=116/120 isolates) being from 2023<sup>43</sup>). There were three isolates among this 10-SNP-  
423 surveillance-cluster in the pre-outbreak data analysed in Figure 1 (Extended data). These  
424 isolates (from 2019 and 2020) contained CRO resistance but did not contain pWPMR2.  
425 However, the 120 outbreak isolates from 2022 – 2023 contain pWPMR2 further highlighting  
426 the association of pWPMR2 in new outbreaks of highly drug-resistant bacteria (Extended  
427 data).

## 428 **Conclusions**

429 Here we have identified that auxiliary *metG* carried by the phage plasmid pWPMR2 is  
430 associated with evolution of bacterial lineages on an AMR trajectory; in this case *Shigella* sp.  
431 circulating in STN. Laboratory studies demonstrated that expression of auxiliary *metG*  
432 facilitated survival of antimicrobial insult and predisposed to the evolution of AMR, but at a  
433 significant fitness cost. This substantial fitness cost is consistent with the apparent bet-hedging  
434 ecology of *metG* borne pWPMR2 in bacterial populations. Specifically, pWPMR2 is borne at  
435 low, sometimes even partial copy numbers (i.e. where infecting pool would have cells with a  
436 mixture of 0 or 1 pWPMR2 copies per cell) which would facilitate many cells avoiding the  
437 significant fitness cost, while leaving a small population able to survive antimicrobial treatment.  
438 The mutated version of *metG* borne by pWPMR2 ( $metG_{PP}$ ) not only reduced the fitness cost,  
439 but introduced similarly stochastic population dynamics through single-cell variability in  
440 dormancy exit and cell growth under antimicrobial exposure that was not seen for the wildtype  
441 ( $metG_{WT}$ ). And finally, as a phage plasmid, pWPMR2, may not actually need its bacterial host  
442 to survive antimicrobial treatment to be passed on, with phage particles simply reinfecting new  
443 hosts once available. Collectively, this indicates that *metG*-bearing pWPMR2 has several  
444 ecological hedges to offer substantial phenotypic advantages under antimicrobial selection  
445 whilst minimising its high fitness cost.

446

447 These mechanistic insights are entirely consistent with ‘nature’s experiment’ captured in the  
448 temporospatial dynamics of pWPMR2. Specifically, pWPMR2 preceding AMR emergence and  
449 being distributed among other clinically relevant and commensal organisms, as well as the

450 detection of other potentially mobilisable *metG* bearing mobile genetic elements in other  
451 bacteria. Concerningly, and perhaps potentiating any services to the evolution of AMR, is that  
452 the persister phenotype induced by auxiliary *metG*<sub>PP</sub> expression might also act to also subvert  
453 immunological responses and contribute to chronic infections, which have been observed for  
454 some strains of sexually transmissible shigellosis<sup>44,45</sup> and many other AMR pathogens.  
455 Hence, pWPMR2 and similar 'hopeful monster' MGEs may be, or may increasingly emerge  
456 as, common pathogen adaptations that persist in microbial communities and mobilise among  
457 pathogens.

458  
459 In the face of that possibility, there are several important avenues of future work here.  
460 Uncovering the fundamental biology of pWPMR2 and other tRNA ligase-bearing mobile  
461 genetic elements in their hosts should be explored. These studies should include aspects of  
462 transmission, evolution, and population ecology, as well as mechanistic pathways around  
463 gene regulation, expression, and functional impacts for the host. The natural distribution of  
464 genetic features that have been detected here should be explored more fully. For example,  
465 the screen for the distribution of pWPMR2 (Fig3B) did not detect pWPMR2var (Extended  
466 data). Hence, the distribution of pWPMR2var, other *metG* (and other tRNA ligase) bearing  
467 mobile genetic elements detected (Extended data), alongside more targeted analyses  
468 screening datasets of other known successful AMR bacterial pathogen sublineages for copy  
469 number variation in *metG* and other tRNA ligases. These works will determine the extent to  
470 which auxiliary tRNA ligases are employed as an evolutionary adaptation in bacterial  
471 populations and provide critical information on the underpinning biological pathways.

472  
473 To end, perhaps the biggest lesson from this work is the value of data driven biology for  
474 naturally evolving pathogen populations. We have, as a global public health community,  
475 sequenced >2000 pathogenic strains of bacteria containing pWPMR2 since 2004 without  
476 understanding its significance. There are two important lessons from this for future  
477 microbiological surveillance in the genomic era. The first is that we have an overly narrow  
478 focus on certain phenotypes in facing the AMR crisis. While the scientific community has  
479 known of tolerance and persistence for decades, these phenotypes are not part of routine  
480 surveillance (owing partly to a focus on patient-level outcomes). Our work highlights the need  
481 to consider more broadly what phenotypes drive bacterial lineages to epidemiological  
482 success. The second issue highlighted is an over-reliance on databases. Bacterial AMR will  
483 not stop evolving as we need to sustain life saving (though responsible) antimicrobial use. To  
484 this end, we are fortunate to now be in the genomic surveillance era facilitating enhanced  
485 taxonomic nomenclature and well-maintained feature databases. However, we also need agile  
486 systems to detect and investigate changes in pathogen genetic make-ups that we do not  
487 understand if we are to better connect pathogen evolution with public health outcomes.

## 488 **Methods (2295 words)**

### 489 *Phylogenetic reconstruction*

490 Short reads of 3745 *S. sonnei* isolates went through the following quality control procedures:  
491 raw read data were downloaded from the Sequence Read Archive (Bioproject: PRJNA248792,  
492 Supplementary Table). Reads were filtered using Trimmomatic v0.39, residual Illumina  
493 adapter sequences were removed, the first and last three base pairs in a read were trimmed,  
494 before a sliding window quality trimming of four bases with a quality threshold of 20 were  
495 applied, and reads of less than 36 bp (after trimming) were removed  
496 (ILLUMINACLIP:PE\_All.fasta:2:30:10:2:keepBothReads SLIDINGWINDOW:4:20 LEADING:3  
497 TRAILING:3 MINLEN:36)<sup>46</sup>. The coverage of the resulting file was estimated against the size  
498 complete reference genome *S. sonnei* 53G (Accession: NC\_016822.1) and down sampled to  
499 ~100 x coverage. Musket v1.1<sup>47</sup> was applied for k-mer spectrum read correction using a k-  
500 mer size of 31bp. The processed reads were then mapped to *S. sonnei* reference genome  
501 53G using snippy v4.6.0 (<https://github.com/tseemann/snippy>), resulting in a core genome  
502 alignment of 4,988,504bp in size. After filtering out polymorphic sites within recombined  
503 regions using Gubbins<sup>48</sup> with marginal ancestral state reconstruction implemented, 32,294  
504 polymorphic sites unaffected by recombination were kept for the final phylogenetic tree  
505 reconstruction. A maximum likelihood phylogenetic tree reconstructed was performed using  
506 iqtree v2.3.6 with a General Time Reversible (GTR) substitution model with 4 gamma rate  
507 categories and 10,000 ultrafast bootstraps to provide approximately unbiased branch support  
508 values<sup>49</sup>. A second phylogenetic reconstruction of the evolutionary relationships among 172  
509 representative isolates from the 3745 *S. sonnei* isolates and 123 isolates from MSM-  
510 associated *bla*<sub>CTX-M-15</sub> outbreak<sup>43</sup> short reads of 295 isolates went through quality control  
511 procedures as described in *Determining depth of coverage and variant calling* below. Then, a  
512 phylogenetic tree inferred similarly to above from 5,942bp polymorphic sites unaffected by  
513 recombination.

514

### 515 *Identification of sexual transmission network lineages*

516 Out of 3745 *S. sonnei* isolates, 1383 isolates with demographic data combination of male,  
517 adult and without travel history to high-risk countries were given presumptive MSM status  
518 (pMSM). Ancestral state reconstruction of each internal node in the phylogenetic tree based  
519 on the pMSM status of each isolate (tree tips) was performed using MrBayes<sup>50</sup> through R  
520 implementation, provided by the package MBASR<sup>51</sup>. The pMSM status of each isolate was  
521 refined by the reconstructed ancestral status of their most adjacent nodes, as STN lineages  
522 are typically identified by an over-representation of isolates derived from pMSM (see  
523 references below). Through plotting the frequency distribution histogram of pMSM  
524 probabilities of the most adjacent node for each isolate, pMSM probabilities greater than 0.8  
525 were defined as pMSM (Extended data). For defining STN lineages, all isolates descending  
526 from each internal node were defined as belonging to a lineage with the node being the most  
527 recent common ancestor. Then, iterating through each node in the tree, a STN lineage was  
528 defined when more than 75% of the isolates in the lineage were pMSM. This approach is an  
529 extension of, and in line with, previous work and validated surveillance practices<sup>12</sup>. To avoid  
530 complete reconstruction of the tree as pMSM, and reflecting the recent emergence of sexually  
531 transmissible shigellosis, only the first and second nodes that were most adjacent to the tree  
532 tips were used in STN lineages definition.

533

### 534 *Bacterial genome wide association analysis*

535 Unitig-based bGWAS was run on 3,745 *S. sonnei* isolates with the 1,028 isolates belonging  
536 to MSMA lineages being a binary phenotype. Unitigs counting was performed using unitig-  
537 caller (<https://github.com/bacpop/unitig-caller>). The presence-absence matrix of the unitigs  
538 was associated with the binary phenotype belonging to MSMA lineages through computing  
539 terminal association scores in treeWAS v1.1<sup>21</sup>. Unitigs with the highest absolute association  
540 scores showed presence-absence patterns that were the most significantly associated with  
541 the phenotype. A minor allele frequency filter of 0.05 was applied and associated unitigs with  
542 association score of greater than 0.66 were examined by the investigative team for further  
543 follow up.

#### 544 *Determining depth of coverage and variant calling*

545 Illumina reads for 3745 *S. sonnei* isolates were trimmed using fastp v0.23.4<sup>52</sup>, using the  
546 following options, in the order as appear: auto-detection for adapter for pair-end data (--  
547 detect\_adapter\_for\_pe), move a sliding window of size 4bp from front (5') to tail, drop the  
548 bases in the window if its mean quality is less than 20, stop otherwise (--cut\_front), move a  
549 sliding window of size 4bp from tail (3') to front, drop the bases in the window if its mean quality  
550 is less than 20, stop otherwise (--cut\_tail), global trimming at front and tail for 15 bp (--  
551 trim\_front1 15, --trim\_front2 15), detect and trim polyG in read tails in minimum length of 10  
552 bases (--trim\_poly\_g), detect and trim polyX in read tails in minimum length of 10 bases (--  
553 trim\_poly\_x).

554 The relative depth of pWPMR2 coverage was determined by mapping trimmed short reads  
555 using Bowtie2<sup>53</sup> to a concatenated reference that contained the following components:  
556 SRR5005407 chromosome (Nanopore contig 1, 4 819 329bp), pSRK100 (contig 8, 65 728bp)  
557 and P-P (contig 9, 108 107bp), separated by strings of 500xN. Final destination of any read  
558 with multiple equally good alignments was randomly reported as default setting. The relative  
559 depth of coverage for each isolate was obtained from the average read depth for the  
560 pWPMR2, normalised by that of the chromosome using Samtools v 1.19<sup>54</sup>. PCR duplicates  
561 were marked using Samtools v 1.19<sup>54</sup>.

562 For copy number determination and variant calling in *metG*, trimmed short reads were mapped  
563 using GEM3<sup>55</sup> to SRR5005407 chromosome (contig 1) only, followed by marking PCR  
564 duplicates. For *metG* variant calling, the number of reads supporting each allele in each variant  
565 position in the *metG* gene region were extracted using bcftools v1.19 mpileup command. They  
566 were then converted into .bcf file using bcftools call command, with the following options  
567 applied: output all alternate alleles in the alignments regardless of if they appear in any of the  
568 final genotype (-A), haploid (--ploidy 1), and alternative model for multiallelic and rare-variant  
569 calling (-m). For each variant position in each sample, the presence of an alternative allele  
570 was only defined when it was supported by at least 40 reads. Alternative allele proportion was  
571 calculated by the number of reads supporting the alternative allele divided by the total read  
572 depth of the position in a sample. Copy number of *metG* was obtained based on the same  
573 mapping, by computing its average read depth for each isolate, normalised by that of  
574 chromosome using Samtools v1.19. PCR duplicates were marked using Samtools<sup>54</sup>.

#### 575 *Genetic analyses of pWPMR2*



576 The circular topology of pWPMR2 (Nanopore contig 10) and pWMPR2var (Nanopore contig  
577 8) was confirmed by assembling the Nanopore reads of SRR5005407 and SRR13013630  
578 respectively using Flye v2.9.5-b1801<sup>56</sup>. Assembled contigs were visualised using Bandage  
579 v0.9.0.<sup>57</sup> Prior assembly, adapter sequences were trimmed and reads with internal adapter  
580 were discarded using Porechop v0.2.4 (<https://github.com/rrwick/Porechop>). Quality score  
581 and length of remaining reads were visualised using NanoPlot v1.43.0<sup>58</sup>, then reads of less  
582 than 150bp and with quality score less than 10 were filtered out using NanoFilt v2.8.0<sup>59</sup>.

583 Detection of phage sequences, plasmid specific sequences, AMR genes and defence systems  
584 were performed by running pWPMR2 through PHASTEST v3.0<sup>60</sup>, PlasmidFinder v2.1<sup>61,62</sup>,  
585 AMRfinderPlus v3.12.8<sup>63</sup>, and DefenseFinder<sup>64,65</sup>. We determined the taxonomy of pWPMR2  
586 using the ViPTree server<sup>66</sup> to generate an all-against-all tBLASTx similarity proteomic tree  
587 against 1,512 related dsDNA prokaryotic viruses from the Virus-Host DB, which utilises  
588 complete genomes from NCBI RefSeq and GenBank<sup>67</sup>, also including examples from each of  
589 the five defined phage-plasmid groups within the SSU5 community<sup>34</sup>. To further explore its  
590 association with clinically relevant organisms we downloaded the genomes of its closest  
591 relatives, as found through a BLASTn search against the NCBI nucleotide collection (nt)  
592 database, selecting sequences with >95% coverage and >98% identity for direct comparison.

593 Five *E. albertii* plasmids were chosen for comparison with pWPMR2 as they represented the  
594 top non-*Shigella* and non-*E. coli* hits in the online nBLAST database showing highest  
595 percentage identity. To screen 66,929 genomes of enteric bacteria available from clinical  
596 cases in the UK for evidence of SSU5-like, pSLy3-like and pWPMR2-like phage plasmids and  
597 additional *metG*, a mapping approach as described previously<sup>68</sup> was used. Briefly, target  
598 genes including *metG* (CP104415.1:54597..56630), *repB* (CP104415.1:22858..24072), and  
599 *repA* (NC\_018843.1:59428..60492) were screened in clinical enteric bacteria derived from UK  
600 reference laboratory routine genomic surveillance, available under BioProjects PRJNA315192  
601 (*E. coli* and *Shigella* spp.) and PRJNA248792 (*Salmonella* spp.)<sup>66,68</sup>.

602 Structural variants between STN-lineage associated pWPMR2 and pWPMR2var, comparison  
603 of near-identical relatives of pWPMR2 in public databases, pWPMR2 and *E. albertii* plasmid  
604 comparison as well as was visualised using EasyFig genome comparison visualiser<sup>69</sup> or  
605 Artemis and ACT<sup>70</sup>. The pWPMR2 sequence was additionally screened against ~2M bacterial  
606 genomes in the AllTheBacteria database v0.3<sup>71</sup> using LexicMap tool v0.4<sup>72</sup>, with a 70%  
607 coverage and 70% identity threshold. Metadata of associated hits were then retrieved using  
608 Entrez Direct (<https://www.ncbi.nlm.nih.gov/books/NBK25501/>).

#### 609 *Long read sequencing of selected isolates*

610 Isolates were grown in TSB overnight with 200 rpm shaking at 37°C and 500µl of the overnight  
611 culture was then used in DNA extraction using either MasterPure total DNA/RNA extraction  
612 kit (Biosearch Technologies) or FireMonkey DNA extraction kit (Revolugen) following  
613 manufacturers' recommendations. Extracted DNA was then quantified using a Qubit before  
614 sending off to be sequenced, analysed and annotated by commercially available  
615 Plasmidsaurus service (<https://www.plasmidsaurus.com/>) using Oxford Nanopore  
616 Technologies (ONT) platform.

617 Analysis of plasmid databases

618 PLSDb database version 2023\_11\_23 was downloaded from [https://ccb-microbe.cs.uni-](https://ccb-microbe.cs.uni-saarland.de/plsdb/plasmids/download/)  
619 [saarland.de/plsdb/plasmids/download/](https://ccb-microbe.cs.uni-saarland.de/plsdb/plasmids/download/) and annotated using Bakta version 1.8.2<sup>73</sup> with the  
620 'full' database. A list of COG categories for tRNA synthetases was downloaded from the COG  
621 database and used as search terms in the Bakta output .gff files. To avoid potentially  
622 misclassified chromosomal sequences in PLSDb, sequences encoding  $\geq 3$  tRNA synthetases  
623 were removed from analyses of tRNA synthetase-encoding plasmids. Plasmid types were  
624 extracted from PLSDb metadata. Analyses were conducted in R using tidyverse<sup>74</sup>.

625

#### 626 *Construction of E. coli strains*

627 *metG*<sub>WT</sub> sequence obtained from the chromosomal copy of *metG* from *S. sonnei* SRR5005407  
628 and the *metG*<sub>PP</sub> sequences obtained from the pWPMR2 of *S. sonnei* SRR5005407 were used  
629 to synthesise the respective versions of *metG* using GeneArt custom synthesis platform  
630 (ThermoScientific). The synthesised genes were then cloned into the inducible pTrcHis2A  
631 vector using the same service and the two resulting plasmids were then transformed into *E.*  
632 *coli* NEB5 $\alpha$  (New England Biolabs, UK) and selected using the ampicillin marker on the vector.  
633 Transformed *E. coli* strains were used in the downstream experiments with 1mM IPTG  
634 (Millipore Sigma, UK) as the inducer to induce the expression of the *metG* genes.

635

#### 636 *Sub-MIC growth curves*

637 Minimum Inhibitory Concentrations (MIC) for each of the *E. coli* strains carrying the two  
638 different versions of *metG* genes on pTrcHis2A vector were determined using E-strips  
639 (Liofilchem, Italy) or broth dilution method for azithromycin (0.25 $\mu$ g/ml), ciprofloxacin (0.008  
640  $\mu$ g/ml) and ceftriaxone (0.008 $\mu$ g/ml). Those strains were then grown in biological and technical  
641 triplicates in TSB containing half of the MIC concentrations of each of the three antibiotics with  
642 and without induction of the *metG* variants. The OD<sub>600nm</sub> values were recorded every 15  
643 minutes using a BioTek Synergy H1 multi-mode plate reader. The resulting data were then  
644 analysed using gcplyr R package<sup>75</sup> and graphs were generated using ggplot2 R package<sup>76</sup>.

645

#### 646 *Experimental evolution study*

647 *E. coli* NEB5 $\alpha$  containing *metG*<sub>WT</sub> and *metG*<sub>PP</sub> on a pTrcHis2a plasmid backbone were  
648 streaked out on TSA plates containing 100 $\mu$ g/ml ampicillin and incubated overnight at 37°C to  
649 obtain isolated colonies of each of the *metG* variant carrying *E. coli*. These isolated colonies  
650 were then inoculated into individual wells of 96 well plates containing either no antibiotics or  
651 AZM, CIP or CRO at a concentration of  $\frac{1}{2}$  MIC value for each and treated as an individual  
652 population. Each 96 well plate contained 47 wells with TSB with IPTG at a final concentration  
653 of 1mM and a control well, 47 wells with no IPTG and a control well. These 96 well plates were  
654 then incubated at 37°C with shaking at 200 rpm for 24 hours before transferring 1% (v/v) into  
655 a fresh 96 well plate containing twice the concentration of each of the antibiotics from the  
656 overnight plate. This was carried on for 12 days with the final concentration of each antibiotic  
657 reaching 1024x MIC. At the end of each of the 24-hour incubation periods, each of the wells  
658 were scored for growth and the number of populations survived was plotted against the  
659 antibiotic concentration using the ggplot2 R package. Statistical analysis for the survival of  
660 each of the populations was performed using the survival R package ([https://CRAN.R-](https://CRAN.R-project.org/package=survival)  
661 [project.org/package=survival](https://CRAN.R-project.org/package=survival)).

#### 662 *Microfluidic single-cell experiment*

663 The microfluidic devices were fabricated following the protocol described in Wedd et al <sup>41</sup>. On  
664 the day before the experiment, the bacterial strains (*metG*<sub>WT</sub>, *metG*<sub>PP</sub>, and background) were  
665 inoculated into TSB and incubated overnight with 200 rpm shaking at 37°C for 18 hours. After  
666 incubation, the cultures were pooled in equal proportions and loaded into the device. Individual  
667 strains were identified based on their chromosomally integrated fluorescence protein markers,  
668 which produced bright signals in dedicated fluorescence channels. Just before the image  
669 acquisition, the two syringes with flow medium (with and without inducer) were prepared, as  
670 well as with and without CRO (50x MIC, 0.4µg/ml). These media were connected to  
671 designated flow lanes in the microfluidic device and switched during the experiment. Time-  
672 lapse multi-colour imaging was conducted to monitor the exit dynamics and post-exit growth  
673 and division of the cells. Images were captured using a Nikon Eclipse Ti2 inverted microscope  
674 with a Hamamatsu C14440-20UP camera. All images were saved in Nikon's ND2 file format  
675 and processed to extract single-cell growth traces using the pipeline described by Wedd et al  
676 <sup>41</sup>, which uses a combination of synthetic training images and machine-learning models for  
677 single-cell segmentation <sup>77</sup>. Cells were tracked across frames using a custom script  
678 (<https://github.com/erezli/MMLineageTracking>). The extracted time-series data were analysed  
679 to determine key growth parameters, such as lag time, using custom Python scripts.

680

### 681 **Acknowledgements**

682 This work was funded by BBSRC (BB/V009184/1) and MRC (MR/X000648/1) project grants.  
683 JPJH is supported by an MRC Career Development Award (MR/W02666X/1). The research  
684 in the Bakshi lab was supported by the Wellcome Trust Award (grant number RG89305), a  
685 University Startup Award for Lectureship in Synthetic Biology (grant number NKXY ISSF3/46),  
686 an EPSRC New Investigator Award (EP/W032813/1) and a seed fund from the School of  
687 Technology at University of Cambridge. CJ, CRB, KSB, LCEM and PR are affiliated to the  
688 National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in  
689 Gastrointestinal Infections at University of Liverpool in partnership with the United Kingdom  
690 Health Security Agency (UKHSA), in collaboration with University of Warwick. SN and PR are  
691 affiliated with the NIHR HPRU in Genomics and Enabling Data at University of Warwick in  
692 partnership with the UKHSA, in collaboration with University of Cambridge and University of  
693 Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS,  
694 the NIHR, the Department of Health and Social Care or UKHSA. PR acknowledges the  
695 Research/Scientific Computing teams at The James Hutton Institute and NIAB for providing  
696 computational resources and technical support for the UK's Crop Diversity Bioinformatics HPC  
697 (BBSRC grant BB/S019669/1), use of which has contributed to the results reported within this  
698 article. The authors would like to thank Professor Wei Shen for his generous support regarding  
699 installing and running AllTheBacteria database and Lexicmap tool. For the purpose of open  
700 access, the authors have applied a Creative Commons Attribution (CC BY) licence to any  
701 Author Accepted Manuscript version arising from this submission.

702

703

704

705

706

707 **Author contributions**

708 Conceptualization – KSB, JPJH, SB, RL

709 Data curation – KSB, LC, SCB, CRB, CJ, RL

710 Formal analysis – CRB, YLT, JPJH, LS, GBB, MDS, CEC, SCB, PR, SB, RL

711 Funding acquisition – KSB, JPJH, CJ, MDS, LC, SB

712 Investigation – KSB, LC, YLT, JPJH, LS, SN, MDS, CEC, SCB, PR, SB, RL

713 Methodology – KSB, LC, YLT, PR, SB, RL

714 Project administration – KSB, MDS

715 Resources – KSB, CJ

716 Supervision – KSB, LC, JPJH, SCB, CJ, SB

717 Visualisation – KSB, CRB, YLT, GBB, MDS, CEC, LS, JPJH, SB, RL

718 Writing – original draft – KSB, YLT, JPJH, GBB, MDS, CEC, SB, RL

719 Writing – review & editing – KSB, LCEM, LC, CRB, YLT, JPJH, SN, MDS, CEC, SCB, PR, CJ,

720 SB, RL, GBB, LS

721 **References**

722

723

724 1. Pulford, C. V. *et al.* Stepwise evolution of Salmonella Typhimurium ST313 causing  
725 bloodstream infection in Africa. *Nat. Microbiol.* **6**, 327–338 (2021).

726 2. Johnson, J. R., Johnston, B., Clabots, C., Kuskowski, M. A. & Castanheira, M. *Escherichia*  
727 *coli* sequence type ST131 as the major cause of serious multidrug-resistant *E. coli*  
728 infections in the United States. *Clinical infectious diseases: an official publication of the*  
729 *Infectious Diseases Society of America* vol. 51 286–294 (2010).

730 3. Banerjee, R. & Johnson, J. R. A new clone sweeps clean: The enigmatic emergence of  
731 *Escherichia coli* sequence type 131. *Antimicrob. Agents Chemother.* **58**, 4997–5004  
732 (2014).

733 4. Edquist, P. J., Makitalo, B., Olsson-Liljequist, B., Soderblom, T. & Wisell, K. T.  
734 Epidemiology extended-spectrum beta-lactamase-producing *Escherichia coli* Sweden  
735 2007–2011. *Clin Microbiol Infect* **20**, O344–O352 (2007).

736 5. Whitmer, G. R., Moorthy, G. & Arshad, M. The pandemic *Escherichia coli* sequence type  
737 131 strain is acquired even in the absence of antibiotic exposure. *PLoS Pathog.* **15**,  
738 e1008162 (2019).

739 6. García-Fernández, A. *et al.* *Klebsiella pneumoniae* ST258 producing KPC-3 identified in  
740 italy carries novel plasmids and OmpK36/OmpK35 porin variants. *Antimicrob. Agents*  
741 *Chemother.* **56**, 2143–2145 (2012).

742 7. Thompson, C. N., Duy, P. T. & Baker, S. The rising dominance of *Shigella sonnei*: An  
743 intercontinental shift in the etiology of bacillary dysentery. *PLoS Negl. Trop. Dis.* **9**,  
744 e0003708 (2015).

745 8. Bennett, R J ,De Silva, P. M. , Bengtsson, R. J. , Horsburgh, M. J. , Blower, T. R. and  
746 Baker, K. S. Temporal GWAS identifies widely distributed putative adhesin contributing  
747 pathogen success *Shigella* spp. *bioRxivorg* (2022).

748 9. Mason, L. C. E. *et al.* The evolution and international spread of extensively drug resistant  
749 *Shigella sonnei*. *Nat. Commun.* **14**, 1983 (2023).

- 750 10. Baker, K. S. *et al.* Intercontinental dissemination of azithromycin-resistant shigellosis  
751 through sexual transmission: a cross-sectional study. *Lancet Infect. Dis.* **15**, 913–921  
752 (2015).
- 753 11. Mitchell, H. D. *et al.* Linkage of whole genome sequencing, epidemiological, and clinical  
754 data to understand the genetic diversity and clinical outcomes of *Shigella flexneri* among  
755 men who have sex with men in England. *Microbiol. Spectr.* **9**, e0121321 (2021).
- 756 12. Mitchell, H. D. *et al.* Use of whole-genome sequencing to identify clusters of *Shigella*  
757 *flexneri* associated with sexual transmission in men who have sex with men in England:  
758 a validation study using linked behavioural data. *Microb. Genom.* **5**, (2019).
- 759 13. Lefèvre, S. *et al.* Rapid emergence of extensively drug-resistant *Shigella sonnei* in  
760 France. *Nat. Commun.* **14**, 462 (2023).
- 761 14. Baker, K. S. *et al.* Horizontal antimicrobial resistance transfer drives epidemics of multiple  
762 *Shigella* species. *Nat. Commun.* **9**, 1462 (2018).
- 763 15. Gilbert, V. L. *et al.* Sex, drugs and smart phone applications: findings from semistructured  
764 interviews with men who have sex with men diagnosed with *Shigella flexneri* 3a in  
765 England and Wales. *Sex. Transm. Infect.* **91**, 598–602 (2015).
- 766 16. Ingle, D. J. *et al.* Co-circulation of multidrug-resistant *Shigella* among men who have sex  
767 with men in Australia. *Clin. Infect. Dis.* **69**, 1535–1544 (2019).
- 768 17. Mason, L. C. E. *et al.* Using demographics of patients to inform treatment of shigellosis in  
769 England. *Lancet Microbe* 101026 (2024).
- 770 18. Worley, J. N. *et al.* Genomic drivers of multidrug-resistant *Shigella* affecting vulnerable  
771 patient populations in the United States and abroad. *MBio* **12**, (2021).
- 772 19. Bardsley, M. *et al.* Persistent transmission of shigellosis in England is associated with a  
773 recently emerged multidrug-resistant strain of *Shigella sonnei*. *J. Clin. Microbiol.* **58**,  
774 (2020).
- 775 20. Hawkey, J. *et al.* Global population structure and genotyping framework for genomic  
776 surveillance of the major dysentery pathogen, *Shigella sonnei*. *Nat. Commun.* **12**, 2684  
777 (2021).

- 778 21. Collins, C. & Didelot, X. A phylogenetic method to perform genome-wide association  
779 studies in microbes that accounts for population structure and recombination. *PLoS*  
780 *Comput. Biol.* **14**, e1005958 (2018).
- 781 22. Jarvest, R. L. *et al.* Nanomolar inhibitors of *Staphylococcus aureus* methionyl tRNA  
782 synthetase with potent antibacterial activity against gram-positive pathogens. *J. Med.*  
783 *Chem.* **45**, 1959–1962 (2002).
- 784 23. Jarvest, R. L. *et al.* Conformational restriction of methionyl tRNA synthetase inhibitors  
785 leading to analogues with potent inhibition and excellent gram-positive antibacterial  
786 activity. *Bioorg. Med. Chem. Lett.* **13**, 1265–1268 (2003).
- 787 24. Girgis, H. S., Harris, K. & Tavazoie, S. Large mutational target size for rapid emergence  
788 of bacterial persistence. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 12740–12745 (2012).
- 789 25. Khare, A. & Tavazoie, S. Extreme antibiotic persistence via heterogeneity-generating  
790 mutations targeting translation. *mSystems* **5**, (2020).
- 791 26. Levin-Reisman, I. *et al.* Antibiotic tolerance facilitates the evolution of resistance. *Science*  
792 **355**, 826–830 (2017).
- 793 27. Wein, T. *et al.* Essential gene acquisition destabilizes plasmid inheritance. *PLoS Genet.*  
794 **17**, e1009656 (2021).
- 795 28. Azam, A.H., Chihara, K., Kondo, K., Nakamura, T., Ojima, S., Tamura, A., Yamashita,  
796 W., Cui, L., Takahashi, Y., Watashi, K., & Kiga, K. Viruses encode tRNA and anti-retron  
797 to evade bacterial immunity. *bioRxiv* (2023).
- 798 29. Lozano-Terol, G. *et al.* Relative impact of three growth conditions on the *Escherichia coli*  
799 protein acetylome. *iScience* **27**, 109017 (2024).
- 800 30. Kremer, M. *et al.* Bacteria employ lysine acetylation of transcriptional regulators to adapt  
801 gene expression to cellular metabolism. *Nat. Commun.* **15**, 1674 (2024).
- 802 31. Baker, K. S., Dallman, T. J., Thomson, N. R. & Jenkins, C. An outbreak of a rare Shiga-  
803 toxin-producing *Escherichia coli* serotype (O117:H7) among men who have sex with men.  
804 *Microb. Genom.* **4**, (2018).

- 805 32. Ahmed, S. A. *et al.* Genomic comparison of *Escherichia coli* O104:H4 isolates from 2009  
806 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding  
807 phage stx2. *PLoS One* **7**, e48228 (2012).
- 808 33. Stephens, C. *et al.* F plasmids are the major carriers of antibiotic resistance genes in  
809 human-associated commensal *Escherichia coli*. *mSphere* **5**, (2020).
- 810 34. Pfeifer, E., Moura de Sousa, J. A., Touchon, M. & Rocha, E. P. C. Bacteria have  
811 numerous distinctive groups of phage-plasmids with conserved phage and variable  
812 plasmid gene repertoires. *Nucleic Acids Res.* **49**, 2655–2673 (2021).
- 813 35. Thorley, K. *et al.* Emergence of extensively drug-resistant and multidrug-resistant *Shigella*  
814 *flexneri* serotype 2a associated with sexual transmission among gay, bisexual, and other  
815 men who have sex with men, in England: a descriptive epidemiological study. *Lancet*  
816 *Infect. Dis.* **23**, 732–739 (2023).
- 817 36. Schmartz, G. P. *et al.* PLSDB: advancing a comprehensive database of bacterial  
818 plasmids. *Nucleic Acids Res.* **50**, D273–D278 (2022).
- 819 37. diCenzo, G. C., Mengoni, A. & Perrin, E. Chromids aid genome expansion and functional  
820 diversification in the family Burkholderiaceae. *Mol. Biol. Evol.* **36**, 562–574 (2019).
- 821 38. Clough, S. E., Elphinstone, J. G. & Friman, V.-P. Plant pathogenic bacterium *Ralstonia*  
822 *solanacearum* can rapidly evolve tolerance to antimicrobials produced by *Pseudomonas*  
823 biocontrol bacteria. *J. Evol. Biol.* **37**, 225–237 (2024).
- 824 39. Levin-Reisman, I., Brauner, A., Ronin, I. & Balaban, N. Q. Epistasis between antibiotic  
825 tolerance, persistence, and resistance mutations. *Proc. Natl. Acad. Sci. U. S. A.* **116**,  
826 14734–14739 (2019).
- 827 40. Zaslaver, A. *et al.* A comprehensive library of fluorescent transcriptional reporters for  
828 *Escherichia coli*. *Nat. Methods* **3**, 623–628 (2006).
- 829 41. Wedd, C. *et al.* Single-cell imaging of the lytic phage life cycle in bacteria. *bioRxiv* (2024)  
830 doi:10.1101/2024.04.11.588870.
- 831 42. Blattman, S. B. *et al.* Identification and genetic dissection of convergent persister cell  
832 states. *Nature* (2024) doi:10.1038/s41586-024-08124-2.



- 833 43. Charles H., Greig D.R., Swift C., Olonade I., Simms I., Sinka K., Baker K.S., Godbole G.,  
834 Jenkins C. Outbreak of sexually transmitted *S. sonnei* *bla*<sub>CTX-M-15</sub> in England: an  
835 epidemiological and genomic investigation. *medRxiv* (2024)  
836 doi:10.1101/2024.10.14.24314996.
- 837 44. Allen, H. *et al.* Evidence for re-infection and persistent carriage of *Shigella* species in adult  
838 males reporting domestically acquired infection in England. *Clin. Microbiol. Infect.* **27**,  
839 126.e7-126.e13 (2021).
- 840 45. Bengtsson, R. J. *et al.* Accessory genome dynamics and structural variation of *Shigella*  
841 from persistent infections. *MBio* **12**, (2021).
- 842 46. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina  
843 sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 844 47. Liu, Y., Schröder, J. & Schmidt, B. Musket: a multistage k-mer spectrum-based error  
845 corrector for Illumina sequence data. *Bioinformatics* **29**, 308–315 (2013).
- 846 48. Croucher, N. J. *et al.* Rapid phylogenetic analysis of large samples of recombinant  
847 bacterial whole genome sequences using Gubbins. *Nucleic Acids Res.* **43**, e15 (2015).
- 848 49. Minh, B. Q. *et al.* IQ-TREE 2: New models and efficient methods for phylogenetic  
849 inference in the genomic era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 850 50. Ronquist, F. *et al.* MrBayes 3.2: efficient Bayesian phylogenetic inference and model  
851 choice across a large model space. *Syst. Biol.* **61**, 539–542 (2012).
- 852 51. Heritage, S. MBASR: Workflow-simplified ancestral state reconstruction of discrete traits  
853 with MrBayes in the R environment. *bioRxiv* (2021) doi:10.1101/2021.01.10.426107.
- 854 52. Chen, S. Ultrafast one-pass FASTQ data preprocessing, quality control, and  
855 deduplication using fastp. *Imeta* **2**, e107 (2023).
- 856 53. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods*  
857 **9**, 357–359 (2012).
- 858 54. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).
- 859 55. Marco-Sola, S., Sammeth, M., Guigó, R. & Ribeca, P. The GEM mapper: fast, accurate  
860 and versatile alignment by filtration. *Nat. Methods* **9**, 1185–1188 (2012).

- 861 56. Kolmogorov, M., Yuan, J., Lin, Y. & Pevzner, P. A. Assembly of long, error-prone reads  
862 using repeat graphs. *Nat. Biotechnol.* **37**, 540–546 (2019).
- 863 57. Wick, R. R., Schultz, M. B., Zobel, J. & Holt, K. E. Bandage: interactive visualization of de  
864 novo genome assemblies. *Bioinformatics* **31**, 3350–3352 (2015).
- 865 58. De Coster, W. & Rademakers, R. NanoPack2: population-scale evaluation of long-read  
866 sequencing data. *Bioinformatics* **39**, (2023).
- 867 59. De Coster, W., D’Hert, S., Schultz, D. T., Cruts, M. & Van Broeckhoven, C. NanoPack:  
868 visualizing and processing long-read sequencing data. *Bioinformatics* **34**, 2666–2669  
869 (2018).
- 870 60. Wishart, D. S. *et al.* PHASTEST: faster than PHASTER, better than PHAST. *Nucleic*  
871 *Acids Res.* **51**, W443–W450 (2023).
- 872 61. Camacho, C. *et al.* BLAST+: architecture and applications. *BMC Bioinformatics* **10**, 421  
873 (2009).
- 874 62. Carattoli, A. & Hasman, H. PlasmidFinder and in silico pMLST: Identification and typing  
875 of Plasmid replicons in whole-genome sequencing (WGS). *Methods Mol. Biol.* **2075**, 285–  
876 294 (2020).
- 877 63. Feldgarden, M. *et al.* AMRFinderPlus and the Reference Gene Catalog facilitate  
878 examination of the genomic links among antimicrobial resistance, stress response, and  
879 virulence. *Sci. Rep.* **11**, 12728 (2021).
- 880 64. Tesson, F. *et al.* Systematic and quantitative view of the antiviral arsenal of prokaryotes.  
881 *Nat. Commun.* **13**, 2561 (2022).
- 882 65. Tesson, F. *et al.* Exploring the diversity of anti-defense systems across prokaryotes,  
883 phages and mobile genetic elements. *Nucleic Acids Res.* (2024)  
884 doi:10.1093/nar/gkae1171.
- 885 66. Nishimura, Y. *et al.* ViPTree: the viral proteomic tree server. *Bioinformatics* **33**, 2379–  
886 2380 (2017).
- 887 67. Mihara, T. *et al.* Linking virus genomes with host taxonomy. *Viruses* **8**, 66 (2016).

- 888 68. Nair, S. *et al.* Presence of phage-plasmids in multiple serovars of *Salmonella enterica*.  
889 *Microb. Genom.* **10**, (2024).
- 890 69. Sullivan, M. J., Petty, N. K. & Beatson, S. A. Easyfig: a genome comparison visualizer.  
891 *Bioinformatics* **27**, 1009–1010 (2011).
- 892 70. Carver, T. J. *et al.* ACT: The Artemis Comparison Tool. *Bioinformatics* **21**, 3422–3423  
893 (2005).
- 894 71. Hunt, M., Lima, L., Shen, W., Lees, J. & Iqbal, Z. AllTheBacteria - all bacterial genomes  
895 assembled, available and searchable. (2024) doi:10.1101/2024.03.08.584059.
- 896 72. Shen, W. & Iqbal, Z. LexicMap: efficient sequence alignment against millions of  
897 prokaryotic genomes. *bioRxiv* (2024) doi:10.1101/2024.08.30.610459.
- 898 73. Schwengers, O. *et al.* Bakta: rapid and standardized annotation of bacterial genomes via  
899 alignment-free sequence identification. *Microb. Genom.* **7**, (2021).
- 900 74. Wickham, H. *et al.* Welcome to the tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).
- 901 75. Blazanin, M. gcplyr: an R package for microbial growth curve data analysis. *BMC*  
902 *Bioinformatics* **25**, 232 (2024).
- 903 76. Wickham, H. Ggplot2. *Wiley Interdiscip. Rev. Comput. Stat.* **3**, 180–185 (2011).
- 904 77. Hardo, G., Noka, M. & Bakshi, S. Synthetic Micrographs of Bacteria (SyMBac) allows  
905 accurate segmentation of bacterial cells using deep neural networks. *BMC Biol.* **20**, 263  
906 (2022).